SSBH 2023

& the 35th Spring Scientific Congr<u>ess of the Korean Society for Bone and Mineral Research</u>

Meet the Expert 1

Steven R. Cummings

San Francisco Coordinating Center, California Pacific Medical Center Research Institute and the Department of Epidemiology and Biostatistics, University of California, San Francisco

*Executive Director, San Francisco Coordinating Center

- *Professor of Medicine, Epidemiology & Biostatistics (Emeritus), University of California, San Francisco
- *Senior Scientist, California Pacific Medical Center Research Institute





Educational Background

1980-1982	Clinical Epidemiology Fellowship, University of California, San Francisco
1977-1980	Internal Medicine, Internship and Residency, University of California, San Francisco
1972-1976	Medical Education (MD), University of California, San Francisco
1965-1969	Undergraduate (BA), Stanford University

Professional Experience

2003-Present	Senior Scientist, California Pacific Medical Center Research Institute
2003-Present	(Emeritus) Professor of Medicine and Epidemiology and Biostatistics
	University of California, San Francisco
1996-Present	Executive Director, San Francisco Coordinating Center

Research Interests

Dr. Cummings is an internal medicine specialist and epidemiologist with expertise in research in osteoporosis, aging, and research design. As Director of the San Francisco Coordinating Center, he has designed and led several landmark studies the epidemiology and prevention of fractures. He also led, or co-led, the pivotal trials of treatments for osteoporosis: alendronate, zoledronate, raloxifene, and denosumab. He organized and has been a leader of the development of guidelines for Goal-directed Treatment for Osteoporosis.

Publications

- 1. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. Cummings SR, Black DM, Thompson DE, et al. JAMA 1998; 280:2077-2082. PMID: 9875874.
- Denosumab for prevention of fractures in postmenopausal women with osteoporosis. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial. N Engl J Med. 2009 Aug 20;361(8):756-65. PMID: 19671655.
- 3. Goal-directed treatment of osteoporosis. Cummings SR, Cosman F, Eastell R, Reid IR, Mehta M, Lewiecki EM. J Bone Miner Res. 2013;28:433-8.
- 4. Goal-Directed Treatment for Osteoporosis: A Progress Report from the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. J Bone Miner Res. 2017,32:3-10.Cummings SR, Cosman F, Lewiecki EM, Schousboe JT, Bauer D, Black D, Brown T, Cheung AM, Cody K, Cooper C, Diez-Perez A, Eastell R, Hadji P, Hosoi T, De Beur SJ, Kagan R, Kiel DP, Reid I, Solomon DH, Randall S.